Market access professionals need

The Canadian Reimbursement and Forecasting Timelines Report provides credible, relevant inputs to help meet your reimbursement forecasting needs.

FEEDBACK ON THIS REPORT

"This report is highly regarded in the industry.  I sit on one of the IMC operational committees, where we often discuss access to therapies.  In speaking with a colleague from [MFR], he mentioned that his company also purchases the CRaFT report. Lately, I have referenced the CRaFT report to help support discussions on access to drugs in certain provinces." 

– Patient Access and Government Affairs Manager
Toronto-based Pharmaceutical Company

"The Canadian Reimbursement and Forecasting Timelines (CRaFT) report is a critical tool that we leverage in Canadian oncology market access discussions with Global teams as well as forecasting. The report provides objective data and timelines with each step throughout the entire reimbursement process, identifies key trends, and summarizes information in an easy-to-read format. I would highly recommend this report if you are looking for a comprehensive overview of the current Canadian reimbursement landscape."

– Director, Market Access
Toronto-Based Pharmaceutical Company

WHAT IS THIS REPORT?

The Canadian Reimbursement and Forecasting Timelines Report April 2021 edition is a 90+ page PowerPoint resource complete with analysis and insights from trusted industry experts.

WHO WOULD BENEFIT?

Market access professionals interested in seeking meaningful inputs into internal reimbursement forecasting analyses.

WHY THIS REPORT?

MORSE analyzed Canadian market access data to create key reimbursement metrics. The Report can support any organization forecasting or planning a Canadian launch by providing critical insights on the public market reimbursement process – from HTA submission to provincial listing.

WHAT DOES THE REPORT INCLUDE?

  • Analysis of pCPA process phase timelines
  • Negotiation trends
  • Provincial time-to-listing trends and market access timelines
  • Sub-analysis of data with stratification by oncology & non-oncology
  • CADTH and pCPA volume metrics
  • pCPA Developments

WHAT TIME PERIOD DOES IT COVER?

The Report focuses on metrics from 2020 but also provides relevant comparisons to 2019 and 2018 to identify trends. Also, it contains formulary listing dates of 2019 & 2020 pCPA Completed Negotiations current as of April 1, 2021.

SNAPSHOT OF THE 2020 HIGHLIGHTS

For a snapshot see our: Fourth Annual pCPA Year in Review Infographic (2020 Edition)

For further information on content and pricing, please complete the form below.

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Canadian Reimbursement and Forecasting Timelines Report - April 2021, April 2021 Edition